California-based CDMO SK pharmteco’s viral vector manufacturing subsidiary in France, Yposkesi, completed its second facility for cell and gene therapies manufacturing in Europe, specializing in the production of adeno-associated virus (AAV) and lentiviral vectors (LVs).
The new production site is situated on the Genopole campus, the largest biotech cluster in France. The 5,000 m2 facility is designed in accordance with current GMP guidelines of the U.S. and Europe. Together with the first bioproduction site, which is also located on the Genopole campus, Yposkesi now operates in 10,000 m2 of cell and gene therapy production space.
Yposkesi is expanding its presence in the anti-cancer and immune cell therapy market with the introduction of LentiSure™, a CAR T-cell platform designed to optimize higher yields, according to company officials.
“It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility,” said Alain Lamproye, CEO of Yposkesi. “This twin site enables us to stay up to pace with demand by producing larger quantities of cell and gene therapy products approved for commercialization. The facility’s design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their client pipelines and commitments, making these treatments more accessible to patients.”
“We anticipate Yposkesi to become a leading global cell and gene therapy (CDMO) through the synergy achieved with the Center for Breakthrough Medicines (CBM), a U.S.-based cell and gene therapy CDMO and a subsidiary of SK pharmteco,” added Yeontae Kim, head of the Bio Investment Center at SK.